Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor

NCT02408016 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02408016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02408016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
May 22, 2015
Completion date
June 30, 2020
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pleural malignant mesothelioma, hla-a*0201 positive cells present, recurrent non-small cell lung carcinoma, recurrent pleural malignant mesothelioma, stage iii non-small cell lung cancer ajcc v7, stage iii pleural malignant mesothelioma ajcc v7, stage iiia non-small cell lung cancer ajcc v7, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7, stage iv pleural malignant mesothelioma ajcc v7, wt1 positive